Hepatitis C infection, Cognition, and inflammation in an Egyptian sample

Farag, Noha H.; Rashed, Hebat-Allah G; Hassan, Marwa; Darweesh, Alaa El-Din M.; Salim, Mohamed; Hassanein, Tarek; Mills, Paul J.

doi:10.1002/jmv.21879

Cited by 9 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19 The cognitive impairment observed in this particular study group could also have been due to non-HIV comorbid infections or conditions. Hepatitis C infection is one such condition but it is rare among HIV-positive individuals in Uganda, with a prevalence of 3%, 20,21 and thus an unlikely cause for the observations made. Tuberculosis with CNS involvement can affect the level of consciousness and consequently the level of cognitive function.…”

Section: Resultsmentioning

confidence: 99%

Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment

et al. 2013

View full text Add to dashboard Cite

Objective: To evaluate the efficacy and safety of minocycline in the management of HIV-associated cognitive impairment. Methods:We enrolled HIV-positive participants with a CD4 count of 250 to 500 cells/mL in a randomized, double-blind, placebo-controlled study. They received 100 mg of minocycline or matching placebo orally every 12 hours for 24 weeks. Cognitive function was measured using the Uganda Neuropsychological Test Battery Summary Measure (U NP Sum) and the Memorial Sloan-Kettering (MSK) scale. The primary efficacy measure was the 24-week change in an average of 9 standardized U NP Sum z scores.Results: Seventy-three participants were enrolled. Of these, 90% were female, 49% were between the ages 30 and 39 years, and 74% had 6 or more years of education. One participant had MSK score of stage 1 (i.e., mild HIV dementia), and 72 participants had MSK stage 0.5 (i.e., equivocal or subclinical dementia) at the baseline evaluation. The minocycline effect on the 24-week change of the U NP Sum compared with placebo was 0.03 (95% confidence interval 20.51, 0.46; p 5 0.37).

show abstract

Section: Resultsmentioning

confidence: 99%

Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Numerous studies have demonstrated increased expression of and serum levels of IL‐6, TNF‐ α, sTNFR, sCD163, and sCD14 among CHC patients compared to healthy controls (Table ) and those with other hepatic diseases such as alcoholic liver disease . In addition, increased serum levels of IL‐10, or disturbances in the ratios of proinflammatory/anti‐inflammatory cytokines TNF‐α/IL‐10 and IL‐6/IL‐10 have been noted among CHC patients compared to healthy controls .…”

Section: Resultsmentioning

confidence: 99%

Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review

Babiker

Hassan

Muhammed

et al. 2019

Clinical Cardiology

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infects 180 million people worldwide and over 4 million people in the United States. HCV infection is a major cause of chronic liver disease and is recognized as a risk factor for clinical cardiovascular disease (CVD). Many studies have shown increased prevalence of cardiac and inflammatory biomarkers in patients with chronic HCV infection (CHC), and though these markers may be used to risk stratify people for cardiac disease in the general population their role in the HCV population is unknown. Patients with CHC have elevated cardiac and inflammatory biomarkers compared to noninfected controls which may play a role in CVD risk stratification. We undertook a systematic review of inflammatory and cardiac biomarkers in people with HCV infection with a focus on the effect of CHC on serum levels of these markers and their utility as predictors of CVD in this population. Medline, EMBASE, and Cochrane databases were searched for relevant articles until June 2019. A total of 2430 results were reviewed with 115 studies included. Our review revealed that HCV infection significantly alters serum levels of markers of inflammation, endothelial function, and cardiac dysfunction prior to HCV treatment, and some of which may change in response to HCV therapy. Current risk stratification tools for development of CVD in the general population may not account for the increased inflammatory markers that appear to be elevated among HCV‐infected patients contributing to increased CVD risk.

show abstract

“…Subgroup analysis by type of illicit drug use or HCV co-infection did not show significant differences in plasma or CSF sCD14, CCL2, or IL-6, consistent with other studies that failed to demonstrate associations between these comorbidities and elevated sCD14 or CCL2. 5, 54 Thus, these comorbidities are unlikely to account for associations between elevated sCD14 and impaired global T scores. The study cohort was from NNTC, which specifically recruits individuals with advanced disease, and CHARTER, which includes a large population of well-controlled HIV+ subjects, to represent a diverse population of HIV-infected individuals with broad range of viral loads.…”

Section: Discussionmentioning

confidence: 99%

Monocyte Activation Markers in Cerebrospinal Fluid Associated With Impaired Neurocognitive Testing in Advanced HIV Infection

Kamat

Lyons

Misra

et al. 2012

JAIDS Journal of Acquired Immune Deficiency Syndromes

160

132

View full text Add to dashboard Cite

Background Activated monocytes/macrophages play a role in severe forms of HIV-associated neurocognitive disorders (HAND), but little is known about mechanisms driving milder forms that are prevalent despite combination antiretroviral therapy (cART). To examine relationships of monocyte activation markers to HAND of varying severity, we compared plasma and CSF biomarker levels to neurocognitive test scores in HIV+ subjects. Methods Plasma and CSF sCD14, CCL2, and IL-6 were measured by ELISA in 67 HIV+ subjects with nadir CD4 <300, and CSF inflammatory biomarkers were measured by multiplex assay in 14 subjects on suppressive cART. Results 82% were on cART, with 31% having undetectable plasma VL. CSF sCD14 was increased in subjects with impaired neurocognitive testing (p=0.02), correlated inversely with global T scores in subjects with detectable but not undetectable plasma VL (p=0.02), and yielded higher AUROC values for predicting impaired T scores (0.659) than plasma or CSF VL and current or nadir CD4 counts in single-marker and multivariate models. CSF sCD14, IL-6, IL-8, CCL2, CCL3, CXCL10, and IFNγ were increased in subjects on suppressive cART regardless of cognitive status and predicted patient class in unsupervised analyses, with IL-8, CCL2, and IFNγ explaining most of the variance. Conclusions CSF sCD14 is associated with impaired neurocognitive testing in HIV patients on nonsuppressive cART, suggesting potential utility as a biomarker to monitor HAND progression. CSF sCD14, IL-6, IL-8, CCL2, CCL3, CXCL10, and IFNγ remain elevated in patients on suppressive cART regardless of cognitive status, implying ongoing intrathecal inflammation even in the absence of clinical manifestations.

show abstract

Hepatitis C infection, Cognition, and inflammation in an Egyptian sample

Cited by 9 publications

References 28 publications

Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment

Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment

Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review

Monocyte Activation Markers in Cerebrospinal Fluid Associated With Impaired Neurocognitive Testing in Advanced HIV Infection

Contact Info

Product

Resources

About